Insulet has announced the full U.S. market release of Omnipod Discover, a web-based data platform built for Omnipod 5. The company says the product delivers data-driven images and personalized insights intended to help patients and healthcare providers make better diabetes management decisions.
The move takes a tool that had been available through a limited U.S. market release and opens it more broadly after what Insulet described as meaningful early uptake. More than 15,000 Omnipod 5 users and over 1,800 healthcare professionals had already adopted Omnipod Discover in the U.S. under the limited program.
What the platform adds
Omnipod 5 is Insulet’s tubeless, wearable Automated Insulin Delivery system, designed to provide automated insulin delivery for up to three days without daily injections. Omnipod Discover adds a software layer on top of that hardware by turning glucose and insulin-delivery information into reports that are sent directly to a patient’s smartphone.
According to Insulet, those reports are meant to show users where to focus their diabetes management efforts. For healthcare providers, the platform produces concise reports that overlay a licensed Ambulatory Glucose Profile with key adjustable pump settings and bolus events to support clinical recommendations.
Dr. Trang Ly, Insulet’s senior vice president and chief medical officer, said in a statement that the point is not simply generating more data but making the data meaningful, so users and providers spend less time gathering information and more time collaborating on diabetes management.
The commercial angle
The broader release matters because diabetes device competition increasingly extends beyond sensors, pumps and insulin-delivery algorithms into the usability of the surrounding data systems. Fierce Biotech noted that competitor Glooko also creates diabetes data from a wearable device, but frames its offering for clinicians rather than patients.
Insulet’s patient-facing approach could strengthen Omnipod 5 retention if users see the software as helping them act on their information between visits rather than only transmitting it to a clinic. That makes Omnipod Discover a commercial support tool as much as a reporting feature.
The company also said the platform is already available outside the U.S. in Spain, Australia, Saudi Arabia, Qatar, Kuwait, UAE and Israel, indicating Insulet is treating the software as part of its broader Omnipod franchise rather than a U.S.-only add-on.
At the American Diabetes Association’s Scientific Sessions in New Orleans, Louisiana, in June, Insulet presented real-world glycemic outcomes using Omnipod Discover. The company said use of the platform was associated with improvements in time in range, with 32% of users seeing a clinically meaningful increase in time in range of 3% or more.
That does not establish a standalone clinical claim for the software, but it gives Insulet an early commercial argument that better presentation of data may support better use of the underlying system. In medtech, that kind of workflow benefit can matter because platforms that fit more naturally into patient routines and clinic visits often become harder to switch away from than hardware specifications alone would suggest.
